The Ahmedabad-based firm has accomplished dosing of Phase-2 on 1,000 members and plans to submit information to India’s drug regulator this month.
Preliminary outcomes present that it’s protected as no security considerations have been noticed up to now, individuals within the know mentioned. “The indications are safe and the trial is under control,” one in all them added.
While the opposite two potential candidates being developed by Indian firms — Bharat Biotech and Serum Institute of India — are each two-dose vaccines, based on a WHO doc Zydus Cadila’s candidate shall be a three-dose vaccine. The firm expects to have last Phase-Three information by March-April 2021.
In an earlier interview with ET, Zydus Cadila chairman Pankaj Patel had mentioned the corporate might be manufacturing 100 million doses to start with, as soon as the vaccine obtained all regulatory permissions.